Clinical Trial: NCT03734016
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2025-03-30 |
Study Overview
Brief Summary
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Official Title
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Intervention / Treatment
- Drug: Zanubrutinib
- Drug: Ibrutinib
Other Study ID Numbers
- BGB-3111-305
- 2018-001366-42
- CTR20190098
- 2018
Start Date (Actual)
2018-11-01
Primary Completion Date (Actual)
2022-08-08
Study Completion Date (Actual)
2024-02-28
Enrollment (Actual)
652
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2025-03-30 |
Study Overview
Brief Summary
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Official Title
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Intervention / Treatment
- Drug: Zanubrutinib
- Drug: Ibrutinib
Other Study ID Numbers
- BGB-3111-305
- 2018-001366-42
- CTR20190098
- 2018
Start Date (Actual)
2018-11-01
Primary Completion Date (Actual)
2022-08-08
Study Completion Date (Actual)
2024-02-28
Enrollment (Actual)
652
Study Type
Interventional
Phase
Phase 3